Statins : Indications and Uses, Safety and Modes of Action.

Intro -- STATINS: INDICATIONS AND USES, SAFETY AND MODES OF ACTION -- STATINS: INDICATIONS AND USES, SAFETY AND MODES OF ACTION -- CONTENTS -- PREFACE -- Chapter 1 STATIN THERAPY FOR CORONARY ARTERY DISEASE BEYOND LIPID LOWERING EFFECT -- ABSTRACT -- INTRODUCTION -- PREVENTION OF CORONARY EVENTS BY STATINS IN CLINICAL TRIALS -- STATINS' LIPID-INDEPENDENT EFFECTS FOR VASCULAR FAILURE -- Statins' Actions for Vascular Endothelial Dysfunction -- Clinical Assessment of Vascular Endothelial Function and Statins' Effects -- Vascular Smooth Muscle Dysfunction and Statin -- Inflammation in the Process of Atherosclelosis -- Anti-Inflammatory Actions of Statins -- Oxidative Stress in Athergenesis -- Anti-Oxydative Effects of Statins -- Effects of Statins on Platelets Activation and Thrombogenesis -- Effects of Statins on Neovascularization -- Effects of Statins on Myocardial Protection -- FUTURE ASPECTS OF STATIN THERAPY FOR CORONARY ARTERY DISEASE -- REFERENCES -- Chapter 2 SIDE EFFECTS OF STATINS IN MONOTHERAPY -- ABSTRACT -- INTRODUCTION -- THE PROBLEM -- TYPES OF ADVERSE EVENTS -- 1. Liver Function -- 2. Renal Function -- 3. Erectile Dysfunction -- 4. Muscular Problems -- Mechanisms: -- The role of exercise: -- Oxidation: -- a) LDL-oxidation: -- b) Isoprostanes: -- 5. Arthritis -- 6. Lupus-Like Syndrome -- 7. Tendinopathy -- 8. Polyneuropathy -- 9. Cognitive Function -- 10. Depression/Suicide -- THERAPEUTIC INTERVENTION -- Coenzyme Q10 -- L-Carnitine -- DISCUSSION -- CONCLUSION -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 3 PRELIMINARY FINDINGS ABOUT THE TRENDS OF THE RENAL HEMODYNAMICS AND THE PROXIES OF CARDIOVASCULAR RISK DURING A SHORT COURSE OF ATORVASTATIN THERAPY IN ESSENTIAL HYPERTENSIVES -- ABSTRACT -- INTRODUCTION -- SUBJECTS AND METHODS -- a) Patients -- b) Study Design -- c) Parameters Evaluated.

d) Assessment of the renal hemodynamical parameters -- e) Statistical Analysis -- RESULTS -- DISCUSSION -- APPENDIX -- Determination of the Inulin: -- a) Serum -- b) Urine -- Determination of the p-Aminohippurate: -- a) Serum -- b) Urine -- REFERENCES -- Chapter 4 BENEFICIAL EFFECTS OF THE ADDITION OF FENOFIBRATE TO STATIN THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTIONS -- ABSTRACT -- INTRODUCTION -- RESEARCH DESIGN AND METHODS -- RESULTS -- DISCUSSION -- CONCLUSIONS -- REFERENCES -- Chapter 5 NON-LIPID LOWERING EFFECTS OF STATINS -- ABSTRACT -- PLEIOTROPIC EFFECTS OF STATINS -- PROLIFERATION, MIGRATION AND APOPTOSIS -- STATINS STABILIZE ATHEROSCLEROTIC PLAQUE BY ENZYME INHIBITION -- ANTI-INFLAMMATORY PROPERTIES -- IMMUNOMODULATING PROPERTIES -- STATIN-MEDIATED PROMOTION OF METABOLIC PATHWAYS -- STATINS PREVENT LDL-PROTEOGLYCAN INTERACTION -- STATINS AND CANCER -- HEMOSTASIS AND THROMBOGENICITY -- STATINS AND RHEUMATOID ARTHRITIS -- STATINS AS ANTI-ARRHYTHMIC THERAPY -- MULTIPLE SCLEROSIS -- CONCLUSIONS -- REFERENCES -- Chapter 6 STATINS IN THE THERAPY OF ACUTE CORONARY SYNDROME -- ABSTRACT -- THE VULNERABLE PLAQUE -- Macrophages -- Endothelium -- Smooth Muscle Cells -- T-lymphocytes -- PLEIOTROPIC EFFECTS OF STATINS -- Anti-Inflammatory Effects of Statins -- Antioxidant Effects of Statins -- Statin Effects on Endothelial Dysfunction -- Statin Effects on Nitric Oxide -- Statins and Endothelin-1 -- Antithrombotic Effects of Statins -- STATINS IN EARLY SECONDARY PREVENTION -- Observational Studies -- Randomized Trials -- STATINS IN THE THERAPY OF ACS -- Animal Studies -- Clinical Studies -- CONCLUSION -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 7 BAD HDL-C RESPONDERS TO STATINS -- ABSTRACT -- INTRODUCTION -- THE FIRST CASE REPORT OF A BAD HDL-C RESPONDER TO STATINS.

CONFIRMATION ABOUT THE EXISTENCE OF BAD HDL-C RESPONDERS -- Data Recording -- Baseline Values -- Treatment Results -- Bad HDL-C Responders -- The Confirmation about Bad HDL-C Responders to Statins -- THE PREVALENCE OF BAD HDL-C RESPONDERS -- Data Collection -- Baseline Values -- Pharmaceutical Treatment -- Treatment Results -- Low HDL-C Levels -- CAUSES FOR BAD HDL-C RESPONSE -- Epidemiological Evidence on Low HDL-C -- Causes for Low HDL-C -- Secondary to Modifiable Risk Factors -- Some Diseases -- Some Drugs -- Possible Causes for bad HDL-C Response -- Compliance to the Diet -- Myalgia -- Metabolic Pathway -- Genetic Profile -- THE GUIDELINES ABOUT LOW HDL-C -- Methods of the Review -- Selected Guidelines -- Diagnostic Threshold Levels -- Treatment Target Levels -- Management of Low HDL-C -- Recommendations from the Guidelines -- THE TREATMENT OF BAD HDL-C RESPONDERS -- Data Collection -- Bad HDL-Responders -- Crossover Results -- Choice between Statins and Fibrates? -- Review and Critical Appraisal of the RCTs with Fibrates -- Treatment of Low HDL-C -- THE FUTURE RESEARCH ON BAD HDL-C RESPONDERS TO STATINS -- CONCLUSION -- THE IMPACT OF THE RESEARCH -- ACKNOWLEDGEMENTS -- REFERENCES -- Chapter 8 BENEFICIAL EFFECTS OF STATINS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MOLECULAR MECHANISM INVOLVED -- ABSTRACT -- INTRODUCTION -- MECHANISM OF ACTION OF STATINS -- MITOGEN-ACTIVATED PROTEIN KINASES (MAPKS) PATHWAYS -- STATINS, CARDIOVASCULAR SYSTEM AND MAPKS -- Statins and ERK Cascade -- Statins and p38 MAPK Cascade -- Statins and JNK Cascade -- Immunomodulatory Effects of Statins and Atherosclerosis -- STATINS, IMMUNOLOGIC SYSTEM AND MAPKS -- Effects of Statins in other Rheumatic Diseases -- Animal and In Vitro Studies -- REFERENCES -- INDEX.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.